Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.50 |
| ▸ | IP6K3 | Q96PC2 | 4/20 | 0.50 |
| ▸ | IP6K2 | Q9UHH9 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8589245 | 0.85 | MEN1 (1.00) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL4019162 | 0.79 | MEN1 (0.66) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL1757999 | 0.79 | ALDH1A1 (0.61) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL7572621 | 0.76 | SMN1; SMN2 (0.54) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL28606963 | 0.73 | MEN1 (0.67) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL19781562 | 0.73 | MEN1 (0.73) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL6171945 | 0.72 | MAPT (0.50) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL7626934 | 0.71 | MAPK1 (0.49) | KMT2AMEN1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL31253421 | 0.71 | MAPT (0.49) | KMT2AMEN1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL26565406 | 0.71 | PRNP (0.56) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | KMT2A 4366/4885MEN1 3959/4885SMN1; SMN2 4539/4885 |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | FNTA, SF3B1, SF3A1 | KMT2A 3988/4885MEN1 142/4885SMN1; SMN2 2934/4885 |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | KMT2A 4281/4885MEN1 72/4885SMN1; SMN2 4108/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | KMT2A 4281/4885MEN1 72/4885SMN1; SMN2 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.